BSKB’s intellectual property attorneys write articles on important and timely topics in intellectual property law across a variety of industries. You’ll find the latest articles and industry insights here.

  • May 20, 2019

    Antibody patents: Danger ahead for biologics

    by John H. Heithaus and Gerald M. Murphy | Life Science IP Review

    John Heithaus and Gerald Murphy discuss the evolution of antibody written description standards at the USPTO.  Read more of their article featured in Life Science IP Review.

  • September 30, 2018

    Overcoming patent rejection

    by MaryAnne Armstrong, Ph.D. & Hailey Bureau Ph. D. | WIPR

    The USPTO's interpretations of four Federal Circuit decisions can be summarized into three key points that help with overcoming rejections under 35 USC § 101, as MaryAnne Armstrong and Hailey Bureau of Birch, Stewart, Kolasch & Birch explain.

  • July 2, 2018

    Case Law as a Guide to Trademark Ownership, Licensing and Enforcement

    by Michael T. Smith | World Trademark Review

    Under common law, ownership is conferred through first use of a trademark– including use by a licensee. Recent case law can help to determine which party has the right to enforce the licensed mark where an infringement suit arises.

  • March 10, 2018

    The Importance of Correctly Identifying Goods and Services

    by Michael T. Smith | World Trademark Review

    Trademark rights are acquired through use of a mark in commerce. Applicants must correctly identify

  • March 5, 2018

    The Importance of Correctly Identifying Goods and Services

    by Michael T. Smith | World Trademark Review

    Trademark rights are acquired through use of a mark in commerce. Applicants must correctly identify the goods and services with which their mark is intended for registration or risk refusal or cancellation.

  • March 5, 2018

    Case Law Shines a Light on Internet Evidence at Motion to Dismiss Stage

    by Lynde F. Herzbach | World Trademark Review

    Assessing the relevance of internet evidence can be a daunting task for rights holders. However, if submitted accurately at the earliest stages, such evidence may sway infringement proceedings.

  • February 21, 2018

    Mutational Analysis of Neuropeptide Y Reveals Unusual Thermal Stability Linked to Higher-Order Self-Association

    by Hailey Bureau, Stephen Quirk, Mandi M. Hopkins, Ryan J. Lusk, Caley Allen, Rigoberto Hernandez and David L. Bain | ACS Omega

    Neuropeptide Y (NPY) is a 36-residue peptide, abundant in the central and peripheral nervous system. The peptide interacts with membrane-bound receptors to control processes such as food intake, vasoconstriction, and memory retention. The N-terminal polyproline sequence of NPY folds back onto a C-terminal α-helix to form a hairpin structure. The hairpin undergoes transient unfolding to allow the monomer to interact with its target membranes and receptors and to form reversible dimers in solution. Using computational, functional, and biophysical approaches, we characterized the role of two conserved tyrosines (Y20 and Y27) located within the hydrophobic core of the hairpin fold. Successive mutation of the tyrosines to more hydrophobic phenylalanines increased the thermal stability of NPY and reduced functional activity, consistent with computational studies predicting a more stable hairpin structure. However, mutant stability was high relative to wild-type: melting temperatures increased by approximately 20 °C for the single mutants (Y20F and Y27F) and by 30 °C for the double mutant (Y20F + Y27F). These findings suggested that the mutations were not just simply enhancing hairpin structure stability, but might also be driving self-association to dimer. Using analytical ultracentrifugation, we determined that the mutations indeed increased self-association, but shifted the equilibrium toward hexamer-like species. Notably, these latter species were not unique to the NPY mutants, but were found to preexist at low levels in the wild-type population. Collectively, the findings indicate that NPY self-association is more complex than previously recognized and that the ensemble of NPY quaternary states is tunable by modulating hairpin hydrophobicity.

  • February 8, 2018

    Prior Art Takes New Shapes: Relying on Non-traditional Prior Art to Invalidate a Patent

    by MaryAnne Armstrong, Ph.D. | Pharmaceutical Patent Analyst

    When we teach kids today about Internet privacy, one of the things that is emphasized is that once something has been posted on the Internet, that posting seemingly takes on a life of its own, with an eternal existence, even if the original poster deletes the posting. Unfortunately, companies have not learned this lesson and temporal items, such as press releases and Internet publications, can come back to haunt a patent owner in the form of invalidating prior art for a post-grant review. The following paragraphs consider ‘non-traditional’ prior art, for example, press releases, Internet publications, drug labels among others, and examine considerations in determining whether such non-traditional prior art can be used as a basis for invalidating a patent.

  • October 16, 2017

    Written Description: A State of Uncertainty

    by John Bailey, John Heithaus, and Ohireime Eromosele | World Intellectual Property Review

    As the bounds of antibody written description have yet to be clarified in the US, what can applicants do to protect their inventions?

  • February 20, 2017

    Exposure to Enhanced Damages After Halo

    by Michael K. Mutter and Shawn A. Hamidinia, Ph.D. | World Intellectual Property Review

    The Halo decision on wilful patent infringement has made it desirable to accumulate evidence of good faith at the time of conduct in order to avoid enhanced damages.

  • November 29, 2016

    Halo: A Fresh Approach to Enhanced Damages

    by Michael K. Mutter and Shawn A. Hamidinia, Ph.D. | World Intellectual Property Review

    A US Supreme Court ruling has changed the landscape for determining damages in cases of wilful patent infringement, as explained in the first edition of a two-part article series.

  • June 15, 2016

    Halo Returns Law of Enhanced Damages to Pre-Seagate Standard

    by Michael K. Mutter | BSKB

    On Monday, June 13, 2016, in Halo Electronics, Inc. v. Pulse Electronics, Inc., 579 U.S. _____; No. 14-1513, the Supreme Court turned back the clock on increased damages under 35 U.S.C. § 284, ruling that the test adopted in In re Seagate Technology, L.L.C., 497 F. 3d 1360 (Fed. Cir. 2007) “unduly confines the ability of the district courts to exercise the discretion conferred to them.”

  • June 6, 2016

    Breathing Life into Patents

    by MaryAnne Armstrong, Ph.D. | Life Sciences Intellectual Property Review

    Applicants wishing to extend their patents’ term of protection do not have to necessarily match up the wording of the claims and the label of the relevant drug for there to be infringement by an ANDA.

  • May 2, 2016

    Discovery In Post-Grant Review vs. Inter Partes Review

    by Lynde F. Herzbach | Law360

    There are many factors that affect which type of post-grant proceeding to file, including timing for filing, estoppel, possible arguments for unpatentability, and available evidence. This article will focus on discovery in post-grant review versus inter partes review and evaluate whether or not additional discovery issues should be a factor in the decision of which proceeding to file. Currently, 10 post-grant reviews have been instituted and the number of patents eligible for post-grant review is growing as more and more America Invents Act patents are issued. For those patents that are eligible for post-grant review, would-be petitioners should evaluate whether a PGR or an IPR is the best option for arguing claims are unpatentable. Based on the limited data available, it appears that even though the number of possible issues in a PGR are broader and the standard for additional discovery is slightly more lenient, it is difficult to obtain additional discovery in a PGR. The ability to seek additional discovery in a PGR is much closer to that of an IPR as opposed to a district court proceeding.

  • March 2, 2016

    What We Know About Sanctions at the PTAB

    by John D.V. Ferman | Law360

    In inter partes review, covered business method and post-grant review proceedings, the Patent Trial and Appeal Board can impose sanctions “against a party for misconduct,” which may include failure to comply with rules and orders; misleading or frivolous arguments or requests; factual misrepresentations; dilatory tactics; abusing discovery or “process;” and a catch-all “improper use of the proceeding.”[1] Possible sanctions include expunging filings; excluding evidence; precluding submission of papers, arguments or issues; awarding attorneys’ fees and “compensatory expenses”; requiring terminal disclaimers; and entering judgment or dismissing a petition.

  • January 28, 2016

    Amending Patent Claims During Inter Partes Review

    by D. Richard Anderson | Corporate Counsel

    The dramatic shift of U.S. patent validity “litigation” from federal district court to the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (PTO)) has created a dilemma for patent owners. Construing claims based on their “broadest reasonable interpretation” (BRI), and applying a relatively low standard of proof at trial, PTAB final decisions have overwhelmingly sided against patent owners. Faced with this new reality, a patent owner involved in a fast-moving America Invents Act (AIA) post-grant proceeding, such as an Inter Partes Review (IPR), must understand all options available for preserving its valuable U.S. patent rights. This article explores one such option – motions to amend – and explains the procedural hurdles, pitfalls and consequences associated with amending claims during an IPR trial.

  • January 27, 2016

    Estoppel Arising From PTAB Trials

    by Gerald M. Murphy, Jr. and Lynde F. Herzbach | Corporate Counsel

    More than two years has passed since the first final written decision in an inter partes review (IPR) in Garmin v. Cuozzo Speed Tech. While the process and rules for post-grant proceedings, such as IPRs, have been clarified by the numerous Patent and Trial Appeal Board (PTAB) decisions and reviews by the U.S. Court of Appeals for the Federal Circuit, one area that still has not been fully tested or developed is the application of estoppel arising from PTAB post-grant proceedings. There is little guidance from district courts as to how the “reasonably could have raised” standard for estoppel of petitioners will be applied. There is also little to no guidance regarding possible patent owner estoppel from either the district courts or the U.S. Patent and Trademark Office (PTO), and such guidance may not be available until enough time has passed for applications related to patents subject to post-grant proceedings are issued by the PTO and tested by district courts.

  • January 26, 2016

    Evidentiary Considerations in PTAB Trials

    by Gerald M. Murphy, Jr. and Lynde F. Herzbach | Corporate Counsel

    Evidence submitted in a trial before the Patent Trial and Appeal Board (PTAB) varies considerably from that submitted in district court litigation in terms of form, substance and method and timing of presentation. A major factor to consider when selecting evidence to present in a PTAB trial is the audience receiving the evidence, which in the case of a PTAB trial is a panel of administrative patent judges (APJs) with formal scientific education and training and years of experience in patent law. Numerous orders regarding motions to exclude have noted the PTAB’s disfavor for such motions, usually noting the strong public policy for making all information filed in a non-jury, quasi-judicial administrative proceeding available to the public, especially in the determination of patentability of claims of an issued patent. This article will explore various issues, from the perspective of the petitioner and the patent owner, that must be considered when selecting evidence to be submitted in a PTAB trial.

  • January 25, 2016

    Attacking a Patent at the PTO: Beware the Real Party in Interest

    by Eugene Perez | Corporate Counsel

    Patents are critical to the success of many companies, where having a good patent portfolio can protect commercial products, keep competitors out of the market and force licensing negotiations. Given the amount of patent litigation, with the latest patent reform laws of 2011, Congress has created new ways to attack and defend patents at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent & Trademark Office (PTO) instead of district court or the International Trade Commission. The idea was to create an alternative forum for contesting patent validity and to reduce the amount of patent litigation. However, around 80 percent of PTAB procedures have concurrent litigation, though sometimes a stay in the litigation is possible. These PTO procedures are called post-grant review (PGR), inter partes review (IPR) and a PGR solely for business method patents (CBM), with IPR being by far the most popular.

  • November 25, 2015

    Getting The Last Word In PTAB Trials

    by Gerald M. Murphy, Jr. and Lynde F. Herzbach | Law360

    Trials before the Patent Trial and Appeal Board are governed by specific rules that provide limited opportunities to make arguments and present evidence. The last substantive filing that is allowed as a matter of right depends on whether or not a patent owner files a motion to amend,[1] and will generally either be the petitioner’s reply or the patent owner’s reply in support of its motion to amend. Nevertheless, procedures are available after the last reply, whereby the other party can possibly have the last word in a PTAB trial. Examples of these procedures include seeking leave to file a sur-reply, to file observations on cross-examination, to file arguments based on the observations on cross-examination, or to seek a waiver of a rule if a party perceives that rule prevents it from having the due process rights to which it is entitled.

Contact Us